JP2012502090A - 脂肪酸油含有乳剤を封入した多糖類カプセル - Google Patents

脂肪酸油含有乳剤を封入した多糖類カプセル Download PDF

Info

Publication number
JP2012502090A
JP2012502090A JP2011526590A JP2011526590A JP2012502090A JP 2012502090 A JP2012502090 A JP 2012502090A JP 2011526590 A JP2011526590 A JP 2011526590A JP 2011526590 A JP2011526590 A JP 2011526590A JP 2012502090 A JP2012502090 A JP 2012502090A
Authority
JP
Japan
Prior art keywords
capsule
fatty acid
emulsion
weight
oil mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011526590A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012502090A5 (enExample
Inventor
ベルジェ，グナー
ハストヴェット，スヴァイン，オラフ
アンデルセン，トーマス
ガセロッド，オラフ
アンデルセン，ペーデル，オスカー
ラーセン，クリスティアン，クライン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pronova Biopharma Norge AS
Original Assignee
Pronova Biopharma Norge AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pronova Biopharma Norge AS filed Critical Pronova Biopharma Norge AS
Publication of JP2012502090A publication Critical patent/JP2012502090A/ja
Publication of JP2012502090A5 publication Critical patent/JP2012502090A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • General Preparation And Processing Of Foods (AREA)
JP2011526590A 2008-09-10 2009-09-10 脂肪酸油含有乳剤を封入した多糖類カプセル Pending JP2012502090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/207,824 2008-09-10
US12/207,824 US20100062057A1 (en) 2008-09-10 2008-09-10 Formulation
PCT/IB2009/006933 WO2010029433A1 (en) 2008-09-10 2009-09-10 A polysaccharide capsule enclosing a fatty acid oil-containing emulsion

Publications (2)

Publication Number Publication Date
JP2012502090A true JP2012502090A (ja) 2012-01-26
JP2012502090A5 JP2012502090A5 (enExample) 2012-11-01

Family

ID=41799505

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011526590A Pending JP2012502090A (ja) 2008-09-10 2009-09-10 脂肪酸油含有乳剤を封入した多糖類カプセル

Country Status (11)

Country Link
US (2) US20100062057A1 (enExample)
EP (1) EP2341901A4 (enExample)
JP (1) JP2012502090A (enExample)
KR (1) KR20110058881A (enExample)
CN (1) CN102209534A (enExample)
AU (1) AU2009290542A1 (enExample)
BR (1) BRPI0918429A2 (enExample)
CA (1) CA2736812A1 (enExample)
EA (1) EA201170433A1 (enExample)
MX (1) MX2011002640A (enExample)
WO (1) WO2010029433A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013129168A1 (ja) * 2012-02-29 2013-09-06 日清オイリオグループ株式会社 カプセル食品およびカプセル含有油脂組成物

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010222648B2 (en) 2009-03-09 2016-07-07 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
WO2011031621A2 (en) * 2009-09-10 2011-03-17 Fmc Corporation High strength seamless alginate capsules
WO2011048493A1 (en) * 2009-10-23 2011-04-28 Pronova Biopharma Norge As Coated capsules and tablets of a fatty acid oil mixture
US8609157B2 (en) 2009-10-30 2013-12-17 Tharos Ltd. Solvent-free process for obtaining phospholipids and neutral enriched krill oils
DE102010001179A1 (de) * 2010-01-25 2011-07-28 Technische Universität Dresden, 01069 Verwendung von Hydrogelen auf Basis guluronsäure- und/oder mannuronsäurehaltiger Polysaccharide zur Behandlung von Beschädigungen des Nervensystems, zur Förderung des Nervenwachstums, zur Behandlung von neurodegenerativen Erkrankungen und zur Kultivierung von Neuronen
GB201006204D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
CA2706270C (en) * 2010-06-03 2020-01-07 Accucaps Industries Limited Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
CA3065589C (en) 2010-06-03 2022-04-26 Catalent Ontario Limited Multi phase soft gel capsules, apparatus and method thereof
EP2658403B1 (en) 2010-12-29 2018-05-02 Abbott Laboratories Nutritional product for improving tolerance, digestion, and lipid soluble nutrient absorption in an infant, toddler, or child
ITMI20111050A1 (it) * 2011-06-10 2012-12-11 Sevecom Spa Uso di emulsionanti in associazione con oleine vegetali in un alimento per animali.
US10052352B2 (en) 2011-06-15 2018-08-21 Stable Solutions Llc Therapeutic application of parenteral krill oil
US8895074B2 (en) * 2011-06-15 2014-11-25 Stable Solutions Llc Therapeutic application of parenteral krill oil
JP5864735B2 (ja) * 2011-06-15 2016-02-17 ステイブル ソリューションズ エルエルシーＳｔａｂｌｅ Ｓｏｌｕｔｉｏｎｓ Ｌｌｃ 非経口オキアミ油の治療用途
WO2013093630A2 (en) 2011-12-22 2013-06-27 Pronova Biopharma Norge As Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof
SG11201403805WA (en) 2012-01-06 2014-08-28 Omthera Pharmaceuticals Inc Dpa-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
AU2013222419B2 (en) 2012-02-21 2017-03-30 Allurion Technologies, Llc Methods and devices for deploying and releasing a temporary implant within the body
US10182932B2 (en) 2012-02-21 2019-01-22 Allurion Technologies, Inc. Methods and devices for deploying and releasing a temporary implant within the body
WO2014074625A1 (en) 2012-02-21 2014-05-15 Allurion Technologies, Inc. Anatomically adapted ingestible delivery systems and methods
WO2013142482A1 (en) 2012-03-20 2013-09-26 Particle Dynamics International, Llc Gelling agent-based dosage form
AU2013240427B2 (en) 2012-03-30 2017-08-03 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US9480651B2 (en) 2012-03-30 2016-11-01 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms
US20160228397A1 (en) 2012-03-30 2016-08-11 Sancilio & Company, Inc. Omega-3 fatty acid ester compositions
US10898458B2 (en) 2012-03-30 2021-01-26 Micelle Biopharma, Inc. Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states
AR095182A1 (es) 2012-05-07 2015-09-30 Omthera Pharmaceuticals Inc Composiciones de estatinas y ácidos grasos omega-3
EP3682875A3 (en) * 2012-06-29 2020-10-21 Amarin Pharmaceuticals Ireland Limited Methods of treating pediatric metabolic syndrome
GB201216385D0 (en) 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
AU2015293628B2 (en) 2014-07-21 2019-06-20 Sevecom S.P.A. Powdered emulsion for animal feed
EP3236954B2 (en) * 2014-12-23 2024-09-04 DuPont Nutrition USA, Inc. Enteric film coating compositions, method of coating, and coated forms
MA41611A (fr) * 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
EP3267977B1 (en) * 2015-03-12 2021-08-11 DuPont Nutrition USA, Inc. Solid dispersions
GB201509606D0 (en) * 2015-06-03 2015-07-15 Anabio Technologies Ltd Microencapsulates containing stabilised marine-derived oil, and methods for production thereof
ES2607715B1 (es) * 2015-10-01 2018-01-17 Solutex Na, Lcc Proceso para la preparación y estabilización de emulsiones con omega-3 mediante redes cristalinas isométricas de derivados de celulosa
KR101634314B1 (ko) * 2015-10-22 2016-06-30 한방약초힐링 농업회사법인주식회사 식물성 오메가-3 함유 기능성 미세분말 제조방법
US20180325785A1 (en) * 2015-11-25 2018-11-15 Asanuma Corporation Method for manufacturing capsule
WO2019165449A1 (en) 2018-02-26 2019-08-29 Allurion Technologies, Inc. Automatic-sealing balloon-filling catheter system
WO2019178444A1 (en) 2018-03-15 2019-09-19 R.P. Scherer Technologies, Llc Enteric softgel capsules
CN108704588B (zh) * 2018-06-29 2020-10-09 广西壮族自治区林业科学研究院 一种微胶囊化酸性水溶液的制备方法
EP4295820B1 (en) 2018-07-06 2025-08-27 Allurion Technologies, LLC Binary fluid control valve system
CN113242723A (zh) 2018-12-13 2021-08-10 阿勒里恩科技公司 增强型流体输送系统
EP3962462A1 (en) * 2019-04-30 2022-03-09 DSM IP Assets B.V. New delivery system for polyunsaturated fatty acids
WO2021220236A1 (en) * 2020-05-01 2021-11-04 Cadila Healthcare Limited Pharmaceutical compositions for combination therapy
US12245962B2 (en) 2023-04-12 2025-03-11 Allurion Technologies, Inc. Balloon sealing and fill valve
US12246163B2 (en) 2023-04-12 2025-03-11 Allurion Technologies, Inc. Automatic-sealing balloon-filling catheter system

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656667A (en) * 1988-08-11 1997-08-12 Norsk Hydro As Fatty acid composition
EP1157692A1 (en) * 2000-05-22 2001-11-28 Quatex N.V. Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
JP2005526819A (ja) * 2002-04-04 2005-09-08 エフエムシー バイオポリマー エイエス ポリサッカライドカプセル及びその製造方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US3682654A (en) * 1970-03-13 1972-08-08 Gen Mills Inc Artificial flavored berries and process of preparing same
US4507327A (en) * 1983-05-23 1985-03-26 Q.P. Corporation Process for preparing edible products in the form of capsules
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
JPS6121070A (ja) * 1984-07-11 1986-01-29 Q P Corp 魚卵様食品の製法
GB2209937B (en) * 1987-09-21 1991-07-03 Depiopharm S A Water insoluble polypeptides
DE3876941D1 (de) * 1987-10-28 1993-02-04 Solvay Umweltchemie Gmbh Zur selektiven abtrennung von metallkationen aus waessrigen loesungen geeignetes teilchenfoermiges mittel, verfahren zu seiner herstellung und seine verwendung.
KR930006431B1 (ko) * 1990-10-11 1993-07-16 재단법인 한국화학연구소 약물의 미세캡슐화 방법
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
EP0573978B1 (en) * 1992-06-12 1999-04-21 Kao Corporation Bath additive composition comprising surfactant-containing seamless capsules and method for producing the capsules.
MY118354A (en) * 1995-05-01 2004-10-30 Scarista Ltd 1,3-propane diol derivatives as bioactive compounds
JP3238350B2 (ja) * 1997-05-27 2001-12-10 三粧化研株式会社 可食性パール状カプセルおよびその製造法
KR100569319B1 (ko) * 1997-10-30 2006-04-07 모리시타 진탄 가부시키가이샤 불포화 지방산 또는 이들의 유도체를 내용물로 하는 캡슐제제 및 그의 제조방법
ATE497384T1 (de) * 1997-12-10 2011-02-15 Cyclosporine Therapeutics Ltd Omega-3 fettsäure enthaltende pharmazeutische zusammensetzungen
US6214376B1 (en) * 1998-08-25 2001-04-10 Banner Pharmacaps, Inc. Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
ES2253147T3 (es) * 2000-03-04 2006-06-01 Cognis Ip Management Gmbh Microcapsulas.
US7264824B1 (en) * 2000-04-13 2007-09-04 Meduna Arzneimittel Gmbh Oral dosage form
AR039170A1 (es) * 2002-03-28 2005-02-09 Bio Dar Ltd Co-granulos de dha y romero y metodos de uso
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
WO2004000201A1 (ja) * 2002-06-24 2003-12-31 Chugai Seiyaku Kabushiki Kaisha 非球形シームレスカプセルの製造方法及び製造装置
US7431986B2 (en) * 2002-07-24 2008-10-07 General Mills, Inc. Encapsulation of sensitive components using pre-emulsification
CA2510465A1 (en) * 2002-12-18 2004-07-08 Pain Therapeutics Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
US20040254357A1 (en) * 2002-12-19 2004-12-16 Zaloga Gary P. Fatty acid phenolic conjugates
ITMI20031617A1 (it) * 2003-08-06 2005-02-07 Fond Carlo E Dirce Callerio Onlus Microcapsule a doppio strato di polisaccaridi utilizzabili

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656667A (en) * 1988-08-11 1997-08-12 Norsk Hydro As Fatty acid composition
EP1157692A1 (en) * 2000-05-22 2001-11-28 Quatex N.V. Composition of fatty acids containing at least 80% by weight of EPA and DHA or their derivatives and its pharmaceutical use
JP2005526819A (ja) * 2002-04-04 2005-09-08 エフエムシー バイオポリマー エイエス ポリサッカライドカプセル及びその製造方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013129168A1 (ja) * 2012-02-29 2013-09-06 日清オイリオグループ株式会社 カプセル食品およびカプセル含有油脂組成物
JPWO2013129168A1 (ja) * 2012-02-29 2015-07-30 日清オイリオグループ株式会社 カプセル食品およびカプセル含有油脂組成物

Also Published As

Publication number Publication date
CA2736812A1 (en) 2010-03-18
US20100062057A1 (en) 2010-03-11
WO2010029433A1 (en) 2010-03-18
US20110262534A1 (en) 2011-10-27
AU2009290542A1 (en) 2010-03-18
EA201170433A1 (ru) 2011-10-31
AU2009290542A2 (en) 2011-03-31
EP2341901A4 (en) 2013-07-17
EP2341901A1 (en) 2011-07-13
KR20110058881A (ko) 2011-06-01
BRPI0918429A2 (pt) 2015-11-24
CN102209534A (zh) 2011-10-05
MX2011002640A (es) 2011-04-07

Similar Documents

Publication Publication Date Title
JP2012502090A (ja) 脂肪酸油含有乳剤を封入した多糖類カプセル
US11523999B2 (en) Compositions comprising a fatty aged oil mixture and a free fatty acid, and methods and uses thereof
CA2781525C (en) Coated capsules and tablets of a fatty acid oil mixture
JP2013508348A5 (enExample)
WO2013072767A1 (en) Compositions and preconcentrates comprising at least one salicylate and omega-3 fatty acid oil mixture
US20150056276A1 (en) Compositions comprising omega-3 fatty acids and vitamin d for psoriasis, and methods and uses thereof
TW201311294A (zh) 含脂肪酸油混合物、界面活性劑與司它汀（ｓｔａｔｉｎ）的組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120907

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140121

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141010

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20141010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20141010

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141104

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20141128